Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder"

Transcription

1 Jpn J Clin Oncol 2002;32(1)14 18 Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder Isao Hara, Hideaki Miyake, Shoji Hara, Akinobu Gotoh, Hiroshi Okada, Soichi Arakawa and Sadao Kamidono Department of Urology, Kobe University School of Medicine, Kobe, Japan Received August 8, 2001; accepted October 4, 2001 Objective: To determine whether the timing of radical cystectomy affects the survival of patients with invasive transitional cell carcinoma (TCC) of the bladder. Methods: Between January 1985 and June 2000, 167 patients underwent radical cystectomy in our institution. Among them, 50 patients who did not receive any perioperative therapies, including chemotherapy and radiotherapy, were divided into two groups, viz. 28 patients who underwent radical cystectomy within 3 months after the primary diagnosis of invasive bladder cancer (group A) and 22 who underwent radical cystectomy more than 3 months after the primary diagnosis (group B), and we then compared several clinicopathological factors and the survival between these two groups. Results: No significant difference was observed in the patients clinicopathological characteristics except for age between these two groups. The median follow-up periods for groups A and B were 53 and 48 months, respectively. In groups A and B, an average of 1.2 (range 1 2) and 1.4 (range 1 3) transurethral resections (TURs) of bladder cancer were performed, respectively (p = 0.83). Twenty of 28 patients in group A underwent orthotopic neobladder replacement, whereas only four of 22 underwent neobladder creation (p = 0.001). The recurrence-free, cause-specific and overall survival rates in group A were significantly higher than those in group B (p < 0.05, p <0.05andp < 0.05, respectively). Final pathological analysis revealed that the distributions of pathological stage, tumor grade and lymph node metastasis were similar between groups A and B; however, the incidence of vascular involvement in group B was significantly higher than that in group A (p < 0.05), despite the lack of a significant difference in the incidence of vascular involvement in TUR specimens between these two groups. Conclusions: These findings suggest that radical cystectomy in the early disease process, especially before the occurrence of vascular involvement, may result in the improvement of survival of patients with invasive TCC of the bladder. Key words: invasive bladder cancer timing of radical cystectomy survival INTRODUCTION Radical cystectomy has evolved to be the gold standard treatment for muscle invasive bladder cancer with an overall 5-year disease-free survival rate of 50 70% (1 3). However, muscleinvasive TCC has an aggressive malignant phenotype that has been shown to have a high propensity for disease-recurrence (1 4). In fact, several studies have reported that recurrence develops in up to 50% of patients who are considered as undergoing curative surgery based on the findings of pathological examinations (1 4). Furthermore, to date, there have been no supportive perioperative therapies that significantly improve For reprints and all correspondence: Isao Hara, Department of Urology, Kobe University School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, , Japan the survival of patients with invasive TCC (5 7). These findings suggest that the currently accepted therapeutic strategy for muscle-invasive TCC should be re-evaluated. Recently, several options, which affect the timing of radical cystectomy for invasive TCC, have been reported. For example, continent urinary diversions have been developed and offered to patients undergoing radical cystectomy (8), among which orthotopic neobladder has become the most favored form of urinary diversion, especially since the risk of surgical complications associated with these procedures has decreased with improved operative techniques and additional surgical experience (8,9). However, various problems caused by urinary diversion remain to be elucidated (8,9) and, therefore, the correct timing of cystectomy and the optimal kind of urinary diversion are still difficult challenges for both the urologist and patient. In 2002 Foundation for Promotion of Cancer Research

2 Jpn J Clin Oncol 2002;32(1) 15 Table 1. Patients characteristics Characteristic Group A (n =28) Group B (n =22) p-value Mean age (range) (years) 64.2 (54 76) 72.5 (59 84) <0.01 Gender (male/female) 23/5 19/3 NS Mean follow-up period (range) (months) 53.3 (8 79) 48.8 (8 66) NS Mean interval from diagnosis of invasive disease to cystectomy (range) (months) 1.9 ( ) 3.6 ( ) <0.05 Numbers of TUR (range) 1.2 (1 2) 1.4 (1 3) NS Clinical T stage (%) T2 27 (96) 21 (95) NS T3 1(4) 1(5) T4 0(0) 0(0) Clinical N stage (%) N0 28 (100) 21 (95) NS N1 or more 0(0) 1(5) Grade* (%) G1 0(0) 0(0) NS G2 4(14) 3 (14) G3 24 (86) 19 (86) Multiplicity (%) Single 9(32) 8 (36) NS Multiple 19 (68) 14 (64) Tumor size (%) <2 cm 13 (46) 11 (50) NS 2 cm 15 (54) 11 (50) Vascular involvement* (%) Negative 14 (50) 13 (59) NS Positive 14 (50) 9 (41) Type of urinary diversion Neobladder 20 (71) 4 (18) <0.001 Incontinent urinary diversion 8(29) 18 (82) *Determined based on the findings of initial transurethral resection (TUR). Not significant. addition, several studies have reported the strategies (10 13), including radical transurethral resection (TUR) plus systemic chemotherapy and intra-arterial chemotherapy plus radiation, for invasive disease in an attempt to preserve the bladder, but it is still unclear whether these options result in improved survival. In the present study, we analyzed the relationship between the interval from the diagnosis of invasive bladder cancer to radical cystectomy and survival in a homogeneous contemporary series of patients with adequate follow-up after treatment with radical cystectomy for invasive TCC of the bladder. PATIENTS AND METHODS Between January 1985 and June 2000, 167 patients with invasive TCC of the bladder underwent radical cystectomy, pelvic lymphadenectomy (bilateral iliac and obturator nodes dissection) and urinary diversion for invasive bladder cancer in our institution. Among them, 50 patients who did not receive any perioperative therapies, including chemotherapy and radiotherapy, were divided into two groups, viz. 28 patients who underwent radical cystectomy within 3 months after the primary diagnosis of invasive bladder cancer (group A) and 22 who underwent radical cystectomy more than 3 months after the primary diagnosis (group B). Bladder cancer was diagnosed by transurethral resection. Physical examination, laboratory studies, chest radiography and intravenous pyelogram (IVP) were performed in all patients. Computed tomography (CT), magnetic resonance imaging and/or abdominal ultrasonography were used for clinical staging. All pathological examinations were performed by a single pathologist. The tumor stage and grade were examined

3 16 Timing of radical cystectomy Table 2. Comparison of survival rates according to the 1997 TNM system and the World Health Organization system, respectively. Vascular involvement was defined only when cancer cells were detected in a thin-walled, endothelium-lined space consisting of blood and/or lymph vessels. We directed particular attention toward artefacts due to peritumoral edema and tissue shrinkage for the detection of vascular involvement. In our institution, concomitant urethrectomy was performed in patients with preoperative histologically confirmed bladder cancer of the urethra and/or prostate. When the patient was physiologically able to tolerate a major operation and perform the normal activities of daily life without compromise, it basically depended on the patient s decision whether orthotopic neobladder replacement or incontinent urinary diversion (ureterocutaneostomy or ileal conduit) was selected, except for one case, that is, neobladder was contraindicated only in patients with urethral involvement. The patients were initially seen 2 months after surgery and then every 3 months for 2 years and every 6 months until disease progression or death. Laboratory studies and urinary cytology were performed every 3 months and chest radiography, abdominal and/or pelvic CT and IVP were carried out every 6 months. For those patients who underwent neobladder replacement, neocystoscopy was performed every 12 months. All survival data were analyzed as the cause-specific survival by the Kaplan Meier technique using a log-rank test. The prognostic value for some parameters was determined by multivariate Cox regression models. The level of significance was set at p < RESULTS Group A (year) Survival rate (%) Group B (year) p-value Recurrence-free survival <0.05 Cause-specific survival <0.05 Overall survival <0.05 In this series, 50 patients underwent radical cystectomy and pelvic lymphadenectomy, including simultaneous orthotopic neobladder replacement in 24 patients (ileal neobladder in one patient, ascending colon neobladder in six patients and sigmoid colon neobladder in 17 patients) and incontinent urinary diversionin26patients(ureterocutaneostomyinfourpatients and ileal conduit in 22 patients). We then divided them into two groups according to the timing of radical cystectomy as described above and the comparison between the patients characteristics of these two groups is summarized in Table 1. No significant difference was observed in the gender, the follow-up period, the number of previous TURs of bladder tumors, tumor size, multiplicity, the distribution of clinical T Table 3. Comparison of final pathological examination Pathological T stage (%) Group A (n =28) Group B (n =22) p-value T2 20 (75) 14 (64) NS T3 6(21) 6 (27) T4 1(4) 2(9) Pathological N stage (%) N0 27 (96) 19 (86) NS N1 or more 1(4) 3 (14) Grade* (%) G1 0(0) 0(0) NS G2 5(18) 4 (18) G3 23 (82) 18 (82) Vascular involvement* (%) Negative 15 (54) 6 (27) <0.05 Positive 13 (46) 16 (73) *Determined based on findings of radical cystectomy specimens. Not significant. stage, N stage and tumor grade and the incidence of vascular involvement between these groups, whereas the mean age in group B was significantly higher than that in group A (p < 0.01) and the ratio of patients who underwent neobladder creation in group A was significantly higher than that in group B (p < 0.001). The median follow-up periods for groups A and B were 53 and 48 months, respectively. As shown in Table 2, the recurrence-free, cause-specific and overall survival rates in group A were significantly higher than those in group B (p < 0.05, p < 0.05 and p < 0.05, respectively). During the observation period in the present study, three and 10 patients in groups A and B, respectively, died of cancer metastases, which were initially diagnosed as retroperitoneal lymph node metastasis in six patients, lung metastasis in five and bone metastasis in two. Final pathological examinations revealed that no significant difference was observed in the distribution of the T stage, N stage and tumor grade, whereas the incidence of vascular involvement in group B was significantly higher than that in group A (p < 0.05) (Table 3). In addition, the mean interval and range from the diagnosis of invasive disease to radical cystectomy inpatients with and without subsequent vascular involvement were 1.7 ( ) and 3.9 ( ) months, respectively (p < 0.01). However, a Cox multivariate regression analysis revealed that only the pathological stage and nodal involvement were independent prognostic predictors, irrespective of gender, age, tumor grade, vascular involvement, tumor size, multiplicity, type of urinary diversion and the interval from the diagnosis of invasive bladder cancer to radical cystectomy (data not shown).

4 Jpn J Clin Oncol 2002;32(1) 17 DISCUSSION The finding that cancer cells have broken through the basement membrane and into the muscular propria reflects a different malignant potential with a propensity for metastases; therefore, muscle-invasive bladder cancer is the usual indication for radical cystectomy and pelvic lymphadenectomy. Despite recent therapeutic advances, such as surgical techniques and perioperative cytotoxic chemotherapy, the survival of invasive bladder cancer patients with pathological risk factors, including advanced stage, lymph node metastasis and vascular involvement, after radical cystectomy remains unsatisfactory (1 5). Furthermore, several therapeutic options for invasive diseases, which affect the timing of radical cystectomy, have become available (10 13). Recently, Sanchez- Ortiz et al. reported that a delay of radical cystectomy of longer than 3 months is associated with advanced pathological stage and decreased survival (14). These findings prompted us to re-evaluate the current therapeutic strategy for invasive TCC of the bladder and here we performed a retrospective analysis in a homogeneous contemporary series of patients who underwent radical cystectomy but not any perioperative therapies for invasive bladder cancer, focusing on the significance of the interval from the diagnosis of invasive disease to radical cystectomy. In this series, the patients characteristics between groups A and B were similar except for age and the ratio of patients with orthotopic neobladder. There were some reasons for these differences in age and the type of urinary diversions between these groups. For example, as part of the informed consent, although age alone was not a contraindication, older patients must be made aware that they may have a more frequent postoperative incidence of postoperative complications, such as nocturnal incontinence, than younger men. The reluctance of elderly patients to undergo radical surgery may also be reflected in this difference. However, because of the similar characters in the remaining factors, this difference may not interfere with the objectives of the present study. The timing of the treatment of bladder cancer is extremely important, since ~20% of new cases are invasive disease and an additional 10% of superficial diseases subsequently progress (15). In this series, no significant difference was observed in the average number of previous TURs between groups A and B, while the prognosis of patients with group A was significantly better than that in group B, suggesting that a delay in performing radical cystectomy could be closely associated with the poorer survival in patients with invasive bladder cancer. In fact, a final pathological examination revealed a higher incidence of vascular involvement in group B than group A, despite the lack of a significant difference in the incidence of vascular involvement in the specimens obtained by TUR. These findings may suggest that vascular involvement frequently occurred during the longer interval from the diagnosis to radical surgery in group B compared with group A, resulting in the poorer survival. Various types of urinary diversion have recently been developed and recent advances in this area provide patients with an improved quality of life (16,17). However, various problems caused by urinary diversion remain to be elucidated, such as metabolic acidosis, urolithiasis, enuresis and impaired body image (8,16), and, therefore, the correct timing of cystectomy and the optimal kind of urinary diversion have been common dilemmas for both the urologist and patient. Recently, some studies have indicated that the option of orthotopic neobladder may influence the decision in favor of earlier cystectomy (9,18,19). In the current series, patients who selected orthotopic neobladder replacement as their urinary diversion tended to receive radical cystectomy earlier than those who selected incontinent urinary diversion. These findings suggest that the orthotopic bladder replacement may decrease the reluctance to perform radical cystectomy early in the disease process. In conclusion, the present findings suggest that radical cystectomy in the early disease process, especially before the occurrence of vascular involvement, may result in the improvement of the survival of patients with invasive TCC of the bladder. We therefore recommend performing radical cystectomy as early as possible after the primary diagnosis of invasive bladder cancer. References 1. Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. JUrol 1999;161: Slaton JW, Swanson DA, Grossman HB, Dinney, CP. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. JUrol1999;162: Hara S, Miyake H, Fujisawa M, Okada H, Arakawa S, Kamidono S, et al. Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder. Jpn J Clin Oncol 2001;31: Ennis RD, Petrylak DP, Singh P, Bagiella E, O Toole KM, Benson MC, et al. The effect of cystectomy and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. JUrol2000;163: Lerner SP, Skinner E, Skinner DG. Radical cystectomy in regionally advanced bladder cancer. Urol Clin N Am 1992;19: Gohji K, Sugino M, Arakawa S, Matsumoto O, Kamidono S, Fujii A, et al. Preoperative adjuvant therapy for urinary bladder cancer. Nippon Hinyoukika Gakkai Zasshi 1990;81: (in Japanese). 7. Miyake H, Gohji K, Hara I, Eto H, Yamanaka K, Arakawa S, et al. Long-term results of neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for locally invasive transitional cell carcinoma of the urothelium. Int J Clin Oncol 1999;4: Turner WH, Bitton A, Studer UE. Reconstruction of the urinary tract after radical cystectomy: the case for continent urinary diversion. Urology 1997;49: Hautmann RE, Paiss T. Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? J Urol 1998;159: Thomas DJ, Roberts JT, Hall RR, Reading J. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up. BJU Int 1999;83: Feneley MR, Mellon JK. Management dilemmas in bladder cancer: radical TUR +/ systemic chemotherapy in the treatment of muscle-invasive bladder cancer. Semin Urol Oncol 2000;18: Miyanaga N, Akaza H, Okumura T, Sekido N, Kawai K, Shimazui T, et al. A bladder preservation regimen using intra-arterial chemotherapy and

5 18 Timing of radical cystectomy radiotherapy for invasive bladder cancer: a prospective study. Int J Urol 2000;7: KageyamaY,OkadaY,AraiG,HyochiN,SuzukiM,MasudaH,etal. Preoperative concurrent chemoradiotherapy against muscle-invasive bladder cancer: results of partial cystectomy in elderly or high-risk patients. Jpn J Clin Oncol 2000;30: Sanchez-Ortiz F, van Aradalen KN, Wein AJ, Markowicz SB, Huang, WC. A prolonged interval between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder cancer. JUrol 2000;165(Suppl): Newling D. Preventing recurrence and progression in superficial bladder cancer. Curr Opin Urol 1996; 6: Frazier HA, Robertson JE, Paulson DF. Complications of radical cystectomy and urinary diversion: a retrospective review of 675 cases in 2 decades. JUrol1992;148: Bjerre BD, Johansen C, Steven K. Health-related quality of life after cystectomy: bladder substitution compared with ileal conduit diversion. A questionnaire survey. Br J Urol 1995;158: Skinner DG, Boyd SD, Lieskovsky G, Bennet C, Hopwood B. Lower urinary tract reconstruction following cystectomy: experience and results in 126 patients using the Kock ileal reservoir with bilateral ureteroileal urethrostomy. JUrol1991;146: Hautmann RE, Miller K, Steiner U, Wenderoth U. The ileal neobladder: 6 years of experience with more than 200 patients. JUrol1993;150:40 5.

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu

More information

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in

More information

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy.

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy. Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,

More information

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura

More information

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,

More information

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma

More information

Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Takashi Ohigashi, Mototsugu Oya, Ken Nakagawa, Akira Miyajima and Masaru Murai

Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Takashi Ohigashi, Mototsugu Oya, Ken Nakagawa, Akira Miyajima and Masaru Murai Assessment of Long-Term Quality of Life Using the FACT-BL Questionnaire in Patients with an Ileal Conduit, Continent Reservoir, or Orthotopic Neobladder Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Takashi

More information

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients

More information

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after

More information

YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI

YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI

More information

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy

Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy European Urology European Urology 41 2002) 440±448 Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy JuÈrgen E. Gschwend a,b,*, Philipp Dahm c, WilliamR.

More information

Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity

Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell

More information

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA

More information

Bone Metastases in Muscle-Invasive Bladder Cancer

Bone Metastases in Muscle-Invasive Bladder Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer

More information

Invasive Bladder Transitional Cell Carcinoma OBJECTIVES

Invasive Bladder Transitional Cell Carcinoma OBJECTIVES Invasive Bladder Transitional Cell Carcinoma UBC Urology Grand Rounds 7 September 2005 John Morrell R5 OBJECTIVES Review role of lymphadenectomy Review role of chemotherapy Review results of bimodal bladder

More information

Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression

Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression Case Study TheScientificWorldJOURNAL (2008) 8, 223 227 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2008.43 Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as

More information

Lymphadenectomy with Cystectomy: Is It Necessary

Lymphadenectomy with Cystectomy: Is It Necessary European Urology European Urology 46 (2004) 457 461 Lymphadenectomy with Cystectomy: Is It Necessary and What Is Its Extent? Mohamed A. Ghoneim *, Hassan Abol-Enein Urology & Nephrology Center, Gomhouria

More information

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma

More information

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) - Dr Anna Lawrence Urologist Auckland Dr Andrew Williams Urologist Auckland Madhu Koya Urologist Auckland Andrew Lienert Urologist Auckland Dr Louise Tomlinson Consultant Gynaecologist Auckland 16:30-18:30

More information

BLADDER CANCER: PATIENT INFORMATION

BLADDER CANCER: PATIENT INFORMATION BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,

More information

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer bs_bs_banner Asia-Pacific Journal of Clinical Oncology 2013; 9: 310 317 doi: 10.1111/ajco.12017 ORIGINAL ARTICLE Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for

More information

Sexuality Preserving Cystectomy and Neobladder (SPCN): Functional Results of a Neobladder Anastomosed to the Prostate

Sexuality Preserving Cystectomy and Neobladder (SPCN): Functional Results of a Neobladder Anastomosed to the Prostate European Urology European Urology 43 (2003) 646 650 Sexuality Preserving Cystectomy and Neobladder (SPCN): Functional Results of a Neobladder Anastomosed to the Prostate W. Meinhardt *, S. Horenblas Department

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National

More information

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.

More information

Chemotherapy Treatment Algorithms for Urology Cancer

Chemotherapy Treatment Algorithms for Urology Cancer Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional

More information

GUIDELINES ON PROSTATE CANCER

GUIDELINES ON PROSTATE CANCER GUIDELINES ON PROSTATE CANCER (Text updated March 2005) A. Heidenreich (chairman), G. Aus, C. Abbou, M. Bolla, S. Joniau, V. Matveev, H-P. Schmid, F. Zattoni Eur Urol 2001;40(2):97-101 Eur Urol 2005;48(4):546-551

More information

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or

More information

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature ISPUB.COM The Internet Journal of Urology Volume 7 Number 1 Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature T Hsieh, J Aragon-Ching, J Saia, T Sotelo Citation T

More information

The Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival

The Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival with metastatic breast and colorectal cancer who are treated with chemotherapy. In breast, lung and colorectal cancer, the value of early chemotherapy in operable localized and locally advanced disease

More information

Long-Term Complications of Conduit Urinary Diversion

Long-Term Complications of Conduit Urinary Diversion Long-Term Complications of Conduit Urinary Diversion Mark S. Shimko,* Matthew K. Tollefson, Eric C. Umbreit, Sara A. Farmer, Michael L. Blute and Igor Frank From the Department of Urology (MSS, MKT, ECU,

More information

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,

More information

ENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA

ENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA ENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA Il. Saltirov, Ts. Petkov, G. Georgiev, K.Petkova Department of Urology and Nephrology, Military Medical

More information

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC.

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC. ISRN Urology Volume 2013, Article ID 405064, 5 pages http://dx.doi.org/10.1155/2013/405064 Research Article Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in

More information

Clinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer

Clinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer Clinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer HITOSHI OJIMA 1, KEN-ICHIRO ARAKI 1, TOSHIHIDE KATO 1, KAORI

More information

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008 Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation

More information

Does skip metastasis or other lymph node parameters have additional effects on survival of patients undergoing radical cystectomy for bladder cancer?

Does skip metastasis or other lymph node parameters have additional effects on survival of patients undergoing radical cystectomy for bladder cancer? Original Article - Urological Oncology Korean J Urol 2015;56:357-364. pissn 2005-6737 eissn 2005-6745 Does skip metastasis or other lymph node parameters have additional effects on survival of patients

More information

GUIDELINEs ON PROSTATE CANCER

GUIDELINEs ON PROSTATE CANCER GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent

More information

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,

More information

Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma

Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI

More information

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

MOLECULAR AND CLINICAL ONCOLOGY 4: , 2016

MOLECULAR AND CLINICAL ONCOLOGY 4: , 2016 MOLECULAR AND CLINICAL ONCOLOGY 4: 839-844, 2016 Clinical outcomes of anti androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial

More information

Bladder Cancer Early Detection, Diagnosis, and Staging

Bladder Cancer Early Detection, Diagnosis, and Staging Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be

More information

M-VAC (methotrexate, vinblastine, d Titlefor poor prognosis patients with ur dose intensity Author(s) HIBI, Hatsuki; OKAMURA, Kikuo; TAKA SHIMOJI, Toshio; MIYAKE, Koji Citation 泌尿器科紀要 (1997), 43(2): 89-96

More information

UPDATE: DIAGNOSIS AND TREATMENT OF MUSCLE- INVASIVE AND METASTATIC BLADDER CANCER IN 2014

UPDATE: DIAGNOSIS AND TREATMENT OF MUSCLE- INVASIVE AND METASTATIC BLADDER CANCER IN 2014 UPDATE: DIAGNOSIS AND TREATMENT OF MUSCLE- INVASIVE AND METASTATIC BLADDER CANCER IN 2014 *Johannes Bründl, Philipp J. Spachmann, Maximilian Burger Department of Urology, University of Regensburg, Caritas

More information

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant

More information

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

Radical Cystectomy for Invasive Bladder Cancer: Results of Multiinstitutional

Radical Cystectomy for Invasive Bladder Cancer: Results of Multiinstitutional Jpn J Clin Oncol 2004;34(1)14 19 Radical Cystectomy for Invasive Bladder Cancer: Results of Multiinstitutional Pooled Analysis Atsushi Takahashi 1, Taiji Tsukamoto 1, Ken-ichi Tobisu 2, Nobuo Shinohara

More information

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized

More information

Radical cystectomy with or without urethrectomy?

Radical cystectomy with or without urethrectomy? Critical Reviews in Oncology/Hematology 47 (2003) 141/145 www.elsevier.com/locate/critrevonc Radical cystectomy with or without urethrectomy? Hein Van Poppel *, Tomas Sorgeloose Division of Urology, University

More information

Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer

Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer Original Article Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer Jianxing Li 1, Qi Wang 2, Bo Xiao 1, Xin Zhang 1 1 Department

More information

Does the Extent of Lymphadenectomy in Radical Cystectomy for Bladder Cancer Influence Disease-Free Survival? A Prospective Single-Center Study

Does the Extent of Lymphadenectomy in Radical Cystectomy for Bladder Cancer Influence Disease-Free Survival? A Prospective Single-Center Study EUROPEAN UROLOGY 60 (2011) 572 577 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Does the Extent of Lymphadenectomy in Radical Cystectomy for Bladder Cancer

More information

Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy

Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy Stephen H. Culp,*, Rian J. Dickstein,*, H. Barton Grossman, Shanna M. Pretzsch,* Sima Porten,* Siamak Daneshmand, Jie Cai,*

More information

Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer?

Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Megumi Hirobe 1, Atsushi Takahashi 1, Shin-ichi Hisasue 1, Hiroshi Kitamura 1, Yasuharu Kunishima 1, Naoya Masumori 1, Akihiko

More information

men with clinically localized prost Citation 泌尿器科紀要 (2005), 51(4):

men with clinically localized prost Citation 泌尿器科紀要 (2005), 51(4): Limited value of perineural Titlespecimens as a predictor of invasio biochem men with clinically localized prost Author(s) Miyake, Hideaki; Sakai, Iori; Harad Hara, Isao Citation 泌尿器科紀要 (2005), 51(4):

More information

Q&A. Collecting Cancer Data: Bladder. Collecting Cancer Data: Bladder 3/3/2011. NAACCR Webinar Series 1. Agenda

Q&A. Collecting Cancer Data: Bladder. Collecting Cancer Data: Bladder 3/3/2011. NAACCR Webinar Series 1. Agenda Collecting Cancer Data: Bladder March 3, 2011 NAACCR 2010-2011 Webinar Series Agenda Coding Moment Bladder Overview Multiple Primary Histology Rules Collaborative Stage Data Collection System Diagnostic,

More information

Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: is there really a difference?

Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: is there really a difference? Diseases of the Esophagus (2008) 21, 596 600 DOI: 10.1111/j.1442-2050.2008.00817.x Original article Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma:

More information

September 10, Dear Dr. Clark,

September 10, Dear Dr. Clark, September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,

More information

Case Report Stereotactic Body Radiotherapy for Localized Ureter Transitional Cell Carcinoma: Three Case Reports

Case Report Stereotactic Body Radiotherapy for Localized Ureter Transitional Cell Carcinoma: Three Case Reports Case Reports in Urology Volume 2015, Article ID 519897, 4 pages http://dx.doi.org/10.1155/2015/519897 Case Report Stereotactic Body Radiotherapy for Localized Ureter Transitional Cell Carcinoma: Three

More information

Care of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary)

Care of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary) Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary) Bannon, F., Ranaghan, L., & Gavin, A. (2014). Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary). N. Cancer Registry,

More information

Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer

Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University

More information

Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer

Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer Turkish Journal of Cancer Vol.31/ No. 2/2001 Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer AHMET ÖZET 1, ALİ AYDIN YAVUZ 1, MURAT BEYZADEOĞLU

More information

Panel: A Case-based Approach to the Management of Bladder Cancer

Panel: A Case-based Approach to the Management of Bladder Cancer Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.

More information

PROTOCOL TITLE LYMPHADENECTOMY IN UROTHELIAL CARCINOMA IN THE RENAL PELVIS AND

PROTOCOL TITLE LYMPHADENECTOMY IN UROTHELIAL CARCINOMA IN THE RENAL PELVIS AND PROTOCOL TITLE LYMPHADENECTOMY IN UROTHELIAL CARCINOMA IN THE RENAL PELVIS AND URETER Participating parties: Principal investigator Nessn H. Azawi,MB.Ch.B. Department of Urology Kogevej 7-13 4000 Roskilde

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

Thymic neoplasms are the most common tumors of

Thymic neoplasms are the most common tumors of Thymic Carcinoma: A Multivariate Analysis of Factors Predictive of Survival in 290 Patients Benny Weksler, MD, Rajeev Dhupar, MD, MBA, Vishal Parikh, BS, Katie S. Nason, MD, MPH, Arjun Pennathur, MD, and

More information

symposium article introduction symposium article

symposium article introduction symposium article Annals of Oncology 17 (Supplement 5): v118 v122, 2006 doi:10.1093/annonc/mdj965 Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin

More information

Metastatic mechanism of spermatic cord tumor from stomach cancer

Metastatic mechanism of spermatic cord tumor from stomach cancer Int Canc Conf J (2013) 2:191 195 DOI 10.1007/s13691-013-0-9 CANCER BOARD CONFERENCE Metastatic mechanism of spermatic cord tumor from stomach cancer Masahiro Seike Yoshikazu Kanazawa Ryuji Ohashi Tadashi

More information

A schematic of the rectal probe in contact with the prostate is show in this diagram.

A schematic of the rectal probe in contact with the prostate is show in this diagram. Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview

More information

Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population

Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population DOI 10.1007/s10147-015-0812-9 ORIGINAL ARTICLE Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population Yasunobu

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1. NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low

More information

Cystoscopy in children presenting with hematuria should not be overlooked

Cystoscopy in children presenting with hematuria should not be overlooked Ped Urol Case Rep 2015; 2(3):7-11 DOI: 10.14534/PUCR.2015310303 PUCR Ped Urol Case Rep PEDIATRIC UROLOGY CASE REPORTS ISSN: 2148 2969 Journal homepage: http://www.pediatricurologycasereports.com Cystoscopy

More information

Vagina. 1. Introduction. 1.1 General Information and Aetiology

Vagina. 1. Introduction. 1.1 General Information and Aetiology Vagina 1. Introduction 1.1 General Information and Aetiology The vagina is part of internal female reproductive system. It is an elastic, muscular tube that connects the outside of the body to the cervix.

More information

Bladder Cancer Basics For the Newly Diagnosed

Bladder Cancer Basics For the Newly Diagnosed Bladder Cancer Basics For the Newly Diagnosed Bladder Cancer Advocacy Network The information in this patient guide is not intended to take the place of medical care or the advice of your doctor. Please

More information

Prostate Case Scenario 1

Prostate Case Scenario 1 Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has

More information

Characteristics of intramural metastasis in gastric cancer. Tatsuya Hashimoto Kuniyoshi Arai Yuichi Yamashita Yoshiaki Iwasaki Tsunekazu

Characteristics of intramural metastasis in gastric cancer. Tatsuya Hashimoto Kuniyoshi Arai Yuichi Yamashita Yoshiaki Iwasaki Tsunekazu ORIGINAL ARTICLE Characteristics of intramural metastasis in gastric cancer Tatsuya Hashimoto Kuniyoshi Arai Yuichi Yamashita Yoshiaki Iwasaki Tsunekazu Hishima Author for correspondence: T. Hashimoto

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

EUROPEAN UROLOGY 64 (2013)

EUROPEAN UROLOGY 64 (2013) EUROPEAN UROLOGY 64 (213) 37 313 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic

More information

Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens

Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens Harman Maxim Bruins,* Hooman Djaladat,* Hamed Ahmadi, Andy

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,

More information

of Urology, Nagoya Memorial Hospital, Nagoya, Japan Keywords: Urothelial carcinoma, cisplatin, gemcitabine, pathological complete response.

of Urology, Nagoya Memorial Hospital, Nagoya, Japan Keywords: Urothelial carcinoma, cisplatin, gemcitabine, pathological complete response. 188 Journal of Analytical Oncology, 2013, 2, 188-194 Pathological Complete Response Induced by the Combination Therapy of Gemcitabine and 24-h Infusion of Cisplatin in Two Cases Initially Diagnosed as

More information

Toru Nakamura 1, Takashi Fukutomi 1, Hitoshi Tsuda 2, Sadako Akashi-Tanaka 1, Kaneyuki Matsuo 1, Chikako Shimizu 1 and Kunihisa Miyakawa 3

Toru Nakamura 1, Takashi Fukutomi 1, Hitoshi Tsuda 2, Sadako Akashi-Tanaka 1, Kaneyuki Matsuo 1, Chikako Shimizu 1 and Kunihisa Miyakawa 3 Jpn J Clin Oncol 2000;30(10)453 457 Changes in Findings of Mammography, Ultrasonography and Contrast-enhanced Computed Tomography of Three Histological Complete Responders with Primary Breast Cancer Before

More information

Adjuvant Therapies in Endometrial Cancer. Emma Hudson

Adjuvant Therapies in Endometrial Cancer. Emma Hudson Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial

More information